Bipolar disorder: Current treatments and new strategies

Cleveland Clinic Journal of Medicine

Volumn 65, Issue SUPPL.1, 1998, Pages

  Sachs, Gary S ^a   Cosgrove, Victoria E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ACETIC ACID DERIVATIVE; AMINE; ANTICONVULSIVE AGENT; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; DRUG DERIVATIVE; FRUCTOSE; GABAPENTIN; LAMOTRIGINE; LITHIUM; TOPIRAMATE; TRIAZINE DERIVATIVE;

BIPOLAR DISORDER; HUMAN; MOOD DISORDER; REVIEW; TREATMENT OUTCOME; TREATMENT REFUSAL;

ACETIC ACIDS; AMINES; ANTICONVULSANTS; BIPOLAR DISORDER; CYCLOHEXANECARBOXYLIC ACIDS; FRUCTOSE; GAMMA-AMINOBUTYRIC ACID; HUMANS; LITHIUM; MOOD DISORDERS; TREATMENT OUTCOME; TREATMENT REFUSAL; TRIAZINES;

EID: 2342617895     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.65.s1.31     Document Type: Article

References (26)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994;350-362.
2. Egeland JA. Bipolarity: the iceberg of affective disorders?. Compr Psychiatry 1983; 24:337-344.
3. Weissman MM, Leaf PJ, Tischler GL, Blazer DG, Karno M, Bruce ML, et al. Affective disorders in five United States communities. Psychol Med 1988;18:141-153.
4. Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1- year prevalence rates of disorders and services. Arch Gen Psychiatry 1993; 50:85-94.
5. Lenox RH, McNamara RK, Papke RL, Manji HK. Neurobiology of lithium: an update. J Clin Psychiatry 1998; 59(suppl 6):37-47.
6. Bowden CL. Key treatment studies of lithium in manic-depressive illness: efficacy and side effects. J Clin Psychiatry 1998;59(suppl 6):13-19.
7. Jefferson JW, Greist JH, Ackerman DL, Carroll JA. Lithium encyclopedia for clinical practice. 2nd edition. Washington, DC: American Psychiatric Press, Inc; 1987:2.
8. Consensus Development Panel. Mood disorders: pharmacologic prevention of recurrences. Am J Psychiatry 1985; 142:469-476.
9. Frances AJ, Kahn DA, Carpenter D, Docherty JP, Donovan SL. The expert consensus guidelines for treating depression in bipolar disorder. J Clin Psychiatry 1998; 59(suppl 4):73-79.
10. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994; 271:918-924.
11. Prien RF, Kupfer DJ, Mansky PA, Small JG, Tuason VB, Voss CB, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate imipramine combination. Arch Gen Psychiatry 1984; 41:1096-1104.
12. Truman C, Sachs GS, Baldassano C, Ghaemi SN. Pattern of illness and duration of mania in bipolar disorder. Presented at the 148th annual meeting of the American Psychiatric Association; 1995; Miami, Florida.
13. Gitlin MJ, Swendsen J, Heller TL, Hammen C. Relapse and impairment in bipolar disorder. Am J Psychiatry 1995; 152:1635-1640.
14. Maj M, Pirozzi R, Magliano L, Bartoli L. Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry 1998; 155:30-35.
15. Bowden CL, Swann AC, Calabrese JR, McElroy SL, Morris D, Petty F, et al. Maintenance clinical trials in bipolar disorder: design implications of the divalproex-lithium-placebo study. Psychopharmacol Bull 1997; 33:693-699.
16. Bowden CL. Long-term prophylaxis treatment: priorities in bipolar disorder. Eur Neuropsychopharmacol 1997; 7:S2-S123.
17. Keck PE Jr, McElroy SL, Strakowski SM, Stanton SP, Kizer DL, Balistreri TM, et al. Factors associated with pharmacologic noncompliance in patients with mania. J Clin Psychiatry 1996; 57:292-297.
18. Johnson RE, McFarland BH. Lithium use and discontinuation in a health maintenance organization. Am J Psychiatry 1996; 153:993-1000.
19. Dunner DL, Fieve RR. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 1974; 30:229-233.
20. Sachs GS. Bipolar mood disorder: practical strategies for acute and maintenance phase treatment. J Clin Psychopharmacol 1996; 16(suppl 1):32S-47S.
21. Sachs GS, Guille C, Demopulos C, Desan P. Atypical antipsychotics: use in bipolar disorder clinic. Presented at the 21st Collegium International Neuropsychopharmacologicum Congress; 1998; Glasgow, Scotland.
22. Lamictal (lamotrigine). Physicians' Desk Reference. 52nd ed. Montvale, NJ: Medical Economics Co Ine; 1998:1043-1048.
23. Young LT. An open trial of gabapentin in bipolar disorder. In: Syllabus and proceedings summary of the American Psychiatric Association Annual Meeting; May 30 June 4, 1998; Toronto, Ontario, Canada. Abstract 77C:150.
24. Neurontin (gabapentin). Physicians' Desk Reference. 52nd ed. Montvale, NJ: Medical Economics Co Ine; 1998:2110-2113.
25. Calabrese JR, Shelton MD, Keck PE, McElroy SL, Werkner JE. Emerging trends in the management of psychiatric illness. In: Syllabus and proceedings summary of the annual meeting of the American Psychiatric Association; May 30-June 4, 1998; Toronto, Ontario, Canada. Abstract NR202.
26. Topamax (topiramate). Physicians' Desk Reference. 52nd ed. Montvale, NJ: Medical Economics Co Ine; 1998:2058-2061.